Short Reads

Pharmaceutical companies beware: excessive pricing enforcement is thriving

Pharmaceutical companies beware: excessive pricing enforcement is thr

Pharmaceutical companies beware: excessive pricing enforcement is thriving

06.12.2018 NL law

On 28 November 2018, the Organization for Economic Cooperation and Development (OECD) held a discussion on excessive pricing by pharmaceutical companies, which is a hot topic in enforcement practice throughout Europe.

Over the last few years, excessive pricing in the pharmaceutical industry has attracted the attention of the European Commission and national regulators. So far, it has led to the adoption of infringement decisions in Italy, UK and Denmark and more enforcement action seems on its way. In a recent paper, the Commission underlined that innovation and risk-taking do not preclude the application of the competition rules to unfair prices. The Dutch Authority for Consumers and Markets (ACM) found that it is possible to strike a balance between innovation and cost control when assessing excessive pharmaceutical prices under the competition rules by adding a touch of fairness into the equation. Clearly, given these developments, there is good reason for pharmaceutical companies to watch this space.

Although the OECD Secretariat and member states have submitted papers, this article focuses on the contributions of the ACM and the Commission.

European Commission

According to the Commission, the pharmaceutical sector is more susceptible to unfair pricing practices than other sectors because of the high inelasticity of demand, especially when patients are dependent on a drug. This is the result of the following factors: (i) patients do not pay for a number of medicines. At the same time prescribers neither consume nor pay them and national health services and insurance companies pay for medicines but have limited influence on prescription or consumption patterns, and (ii) health service providers may have limited bargaining power to negotiate prices with manufacturers.

The Commission acknowledged that the particularities of the pharmaceutical industry, such as product life cycles and the role of regulation by health authorities, need to be taken into account when assessing pricing practices by pharmaceutical companies. These features, however, do not rule out competition rules being applied to unfair pricing practices.

The Commission noted that competition authorities may face difficulties in determining whether prices are excessive, the correct price to adopt as a remedy to competition concerns and how an implemented remedy should be monitored. When considering the methods used to assess whether prices are excessive, the Commission alluded to a test adopted by the European Court of Justice in its seminal judgment in United Brands. This test considers two alternative criteria in determining excessive pricing practices: a price may be (i) unfair in itself or (ii) unfair compared to competing products. However, applying this test is not necessarily straightforward. Recently, for example, the UK Competition Appeal Tribunal found that the Competition and Markets Authority had misapplied the United Brands test in finding that Pfizer and Flynn Pharma unfairly priced their epilepsy drug [see our July 2018 Newsletter]. The Commission acknowledged that there are other tests besides the one adopted in United Brands to establish whether a price is abusive.

ACM

Similarly, in its submission to the OECD, the ACM again stressed that the existence of patent protection does not bar enforcement of the competition law prohibition on excessive pricing. This year the ACM has shown an increased interest in pricing in the pharmaceutical industry [see our March 2018 Newsletter]. More recently, the former chairman of the ACM together with two colleagues published a paper concerning the application of the competition rules to the pharmaceutical industry [see our April 2018 Newsletter]. In its OECD submission the ACM added a new element which was not yet fully developed in its previous paper, i.e. fairness.

In the context of fairness, the ACM argued that a stricter cost-based test should be applied to drugs that involve limited innovation in comparison with drugs that require significant investment in research and development. The ACM considered that the most important factors to take into account for the cost-based test are (i) the probability that a drug will be authorized and successful in the market and (ii) capital costs.

The ACM's proposed framework raises many questions. It is likely that this approach will be tested in future cases. For example, the ACM recently received a complaint against Leadiant Biosciences for allegedly overpricing an orphan drug used for the treatment of a rare genetic disease. The ACM has also launched a sector inquiry into high prices of TNF inhibitors, a type of drug mainly used to treat rheumatisms.

 

This article was published in the Competition Law Newsletter of December 2018. Other articles in this newsletter:

 

 

Team

Related news

09.01.2020 NL law
Deleting WhatsApp chats during dawn raids may cost you dearly

Short Reads - Companies should be aware that the Dutch competition authority (ACM) will not only examine electronic records and emails, but can also check WhatsApp messages during dawn raids. The ACM recently imposed a fine of EUR 1.84 million on a company for non-cooperation with a dawn raid; its highest fine so far for non-cooperation. Several of the company’s employees had left WhatsApp groups and deleted chats before handing over their mobile phones for inspection.

Read more

16.01.2020 NL law
De Amsterdamse milieuzone voor brom- en snorfietsen: voertuigen van een bepaald jaar weren is mogelijk bij ontbreken van een redelijk alternatief

Short Reads - ABRvS 20 november 2019, ECLI:NL:RVS:2019:3865 Deze blog is het vierde deel in een reeks Stibbeblogs over gemeentelijke milieuzones. In 2017 oordeelde de Afdeling over de milieuzone voor personen- en bestelauto’s met dieselmotoren in Utrecht. In 2018 presenteerde de staatssecretaris van Infrastructuur en Waterstaat haar beleid voor harmonisatie van uiteenlopende gemeentelijke milieuzones. Een jaar geleden maakten wij in een FAQ de balans op over de harmonisatie van milieuzones.

Read more

09.01.2020 NL law
Access to the file in Dutch competition procedures: too little too late?

Short Reads - Companies beware: the ACM’s and European Commission’s approach to access to the file are not aligned. According to an interim relief judge, the ACM cannot be forced to grant a company access to a broader set of documents in competition procedures. A potential error in the administrative procedure can be remedied before a court at a later stage. This is different to the right to access to the Commission’s file during administrative procedures, as acknowledged in EU case law.

Read more

10.01.2020 NL law
Is het mededingingsrecht de reddingsboei van zwakke zzp’ers?

Articles - Het toenemende aantal zzp'ers heeft ook mededingingsrechtelijke gevolgen. Volgens de ACM werkt de markt namelijk niet goed als zzp'ers door lage uurtarieven onder het bestaansminimum komen. Jan Truijens Martinez en Simone Evans bespreken in het Tijdschrift voor Arbeidsrecht in Context hoe eventuele belemmeringen die het mededingingsrecht opwerpt bij de bescherming van zzp'ers kunnen worden beperkt en of het mededingingsrecht eigenlijk wel het juiste instrument daarvoor is? 

Read more

09.01.2020 NL law
Competition rules and globalisation to face off in 2020

Short Reads - 2020 will likely revolve around the question whether competition rules should yield to globalisation and digitisation, with suggestions ranging from mere tweaks to competition rules to complementary regulation. Greater cooperation across data protection, consumer protection and competition law appears inevitable. Speedier solutions in more informal settings may become a reality, alongside more frequent use of behavioural remedies.

Read more

Our website uses functional cookies for the functioning of the website and analytic cookies that enable us to generate aggregated visitor data. We also use other cookies, such as third party tracking cookies - please indicate whether you agree to the use of these other cookies:

Privacy – en cookieverklaring